In the non-intestinal pathway, KRAS with PTEN or LKB1 mutations lead to KRAS-driven IPMN progression with additional mutations (SMAD4, TP53, or CDKN2A) to tubular carcinoma [74]. This evidence concerns the gene KRAS and pancreatic intraductal papillary-mucinous neoplasm.